Splendiani G, Passalacqua S, Barbera G, Sturniolo A, Costanzi S, Bartoccioni E, Casciani C U
2d Università Tor Vergata, C.I. Columbus, Roma.
Biomater Artif Cells Immobilization Biotechnol. 1991;19(1):255-65. doi: 10.3109/10731199109117831.
We performed ten plasma perfusion (PP) treatments on eight patients affected by Myasthenia Gravis (MG) with high serum levels of autoantibodies against acetylcholine receptors (anti AChR-AB), and one PP treatment on a patient with MG of probable genetic origin and without specific antibodies. All patients (Osserman group III-IV) had undergone thymectomy and immunosuppressive therapy. Each patient received a treatment cycle of six PP sessions. Clinical conditions were assessed before and after the treatment with evaluation of muscular strength, ventilatory function, and electromyographic testing. Immunologic markers were tested before and after each PP. The patient without specific antibodies showed no improvement with PP and was excluded from our study. All the other patients showed continued improvement, with increased muscle strength and improved respiratory function. Four patients (follow-up 16-24 months) still maintain the clinical improvement; two, unexpectedly relapsed 11-12 months after PP, received a new treatment successfully (follow-up 9-10 month).
我们对8例血清抗乙酰胆碱受体自身抗体(抗AChR-AB)水平高的重症肌无力(MG)患者进行了10次血浆灌注(PP)治疗,并对1例可能为遗传起源且无特异性抗体的MG患者进行了1次PP治疗。所有患者(Osserman III-IV组)均接受过胸腺切除术和免疫抑制治疗。每位患者接受了一个由6次PP治疗组成的治疗周期。在治疗前后通过评估肌肉力量、通气功能和肌电图测试来评估临床状况。在每次PP治疗前后检测免疫标志物。无特异性抗体的患者经PP治疗后无改善,被排除在我们的研究之外。所有其他患者均持续改善,肌肉力量增强,呼吸功能改善。4例患者(随访16 - 24个月)仍保持临床改善;2例患者在PP治疗后11 - 12个月意外复发,成功接受了新的治疗(随访9 - 10个月)。